Bladder Cancer Clinical Trials
A listing of Bladder Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 389 clinical trials
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC)
- 17 views
- 17 Jun, 2022
- 18 locations
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement
The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …
- 243 views
- 10 May, 2022
- 64 locations
Non-Muscle Invasive Bladder Cancer BOND-003
People with Non-Muscle Invasive Bladder Cancer are asked to participate in a research study being conducted by Montefiore Medical Center.
- 1 views
- 03 Aug, 2021
- 1 location
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer
- 142 views
- 08 Nov, 2020
- 1 location
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)
- 229 views
- 25 Mar, 2021
- 1 location
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)
The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose
- 73 views
- 23 May, 2022
- 173 locations
Therapeutic Instillation of Mistletoe (TIM)
The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the time to tumor recurrence. Secondary objective is to evaluate the safety of abnobaVISCUM® 900, in particular, to compare the …
- 58 views
- 13 May, 2022
- 23 locations
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.
- 0 views
- 13 Jun, 2022
- 166 locations
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin (VOLGA)
Enfortumab vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet
- 16 views
- 17 Jun, 2022
- 37 locations
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy [gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC …
- 19 views
- 01 Jul, 2022
- 108 locations